A Phase I/II Trial to Evaluate the Safety and Immunogenicity of a Helper Peptide Vaccine Plus CTLA-4 Blockade in Melanoma Patients (Mel62; 6PAC)
Phase of Trial: Phase I/II
Latest Information Update: 17 Sep 2017
At a glance
- Drugs Ipilimumab (Primary) ; Peptide vaccines
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms Mel62; 6PAC
- 31 Aug 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Aug 2019.
- 21 Aug 2017 Planned number of patients changed from 51 to 27.
- 10 Jun 2017 Biomarkers information updated